Proficient metabolism of irinotecan by a human intestinal carboxylesterase.

Irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11)] is metabolized by esterases to yield the potent topoisomerase I poison 7-ethyl-10-hydroxycamptothecin. One of the major side effects observed with CPT-11 is gastrointestinal toxicity, and we supposed that this might be due to local activation of CPT-11 within the gut. Carboxylesterase (CE) activity was detected in human gut biopsies, and extracts of these tissues converted CPT-11 to 7-ethyl-10-hydroxycamptothecin in vitro. Expression of a human intestinal CE cDNA in COS-7 cells produced extracts that demonstrated proficient CPT-11 activation and conferred sensitivity of cells to CPT-11. These results suggest that gut toxicity from CPT-11 may be due in part to direct drug conversion by CEs present within the small intestine.

[1]  M. Wierdl,et al.  Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. , 2000, Cancer research.

[2]  C. V. Pesheck,et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[3]  M. Dolan,et al.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. , 2000, Cancer research.

[4]  P. Houghton,et al.  Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Ravikumar,et al.  In vitro activation of irinotecan to SN-38 by human liver and intestine. , 1999, Anticancer research.

[6]  P. Houghton,et al.  Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  C. Morton,et al.  Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Wierdl,et al.  Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. , 1998, Cancer research.

[9]  G. Vassal,et al.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Morton,et al.  Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). , 1998, Cancer research.

[11]  T. Langmann,et al.  Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. , 1997, Biochemical and biophysical research communications.

[12]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.

[13]  Y. Pommier,et al.  Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.

[14]  P. Hérait,et al.  Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. , 1994, Journal of the National Cancer Institute.

[15]  P. Houghton,et al.  Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. , 1993, Cancer research.

[16]  T. Yokokura,et al.  Nonlinear pharmacokinetics of CPT-11 in rats. , 1990, Cancer research.

[17]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[18]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[19]  E. Feytmans,et al.  ANALYTICAL STUDY OF MICROSOMES AND ISOLATED SUBCELLULAR MEMBRANES FROM RAT LIVER , 1974, The Journal of cell biology.

[20]  A. Amar‐Costesec,et al.  ANALYTICAL STUDY OF MICROSOMES AND ISOLATED SUBCELLULAR MEMBRANES FROM RAT LIVER , 1974, The Journal of cell biology.

[21]  C. Morton,et al.  Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. , 1998, Cancer research.

[22]  P. Hérait,et al.  Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Hérait,et al.  CPT-11-induced cholinergic effects in cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Hakusui,et al.  Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  S. Guichard,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1998.0364 CPT-11 converting carboxylesterase and topoisomerase I , 2022 .